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Background: NAD(P)H:quinone oxidoreductase (NQO1) is a flavoprotein that catalyzes two-electron reduction and
detoxification of quinones and its derivatives. NQO1 catalyzes reactions that have a protective effect against redox
cycling, oxidative stress and neoplasia. High expression of NQO1 is associated with many solid tumors including
those affecting the colon, breast and pancreas; however, its role in the progression of ovarian carcinoma is largely
undefined. This study aimed to investigate the clinicopathological significance of high NQO1 expression in serous
ovarian carcinoma.
Methods: NQO1 protein expression was assessed using immunohistochemical (IHC) staining in 160 patients with
serous ovarian carcinoma, 62 patients with ovarian borderline tumors and 53 patients with benign ovarian tumors.
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to detect NQO1 mRNA expression levels.
The correlation between high NQO1 expression and clinicopathological features of ovarian carcinoma was evaluated
by Chi-square and Fisher’s exact test. Overall survival (OS) rates of all of ovarian carcinoma patients were calculated
using the Kaplan-Meier method, and univariate and multivariate analyses were performed using the Cox proportional
hazards regression model.
Results: NQO1 protein expression in ovarian carcinoma cells was predominantly cytoplasmic. Strong, positive expression
of NQO1 protein was observed in 63.8% (102/160) of ovarian carcinomas, which was significantly higher than in
borderline serous tumors (32.3%, 20/62) or benign serous tumors (11.3%, 6/53). Importantly, the rate of strong,
positive NQO1 expression in borderline serous tumors was also higher than in benign serous tumors. High expression
of NQO1 protein was closely associated with higher histological grade, advanced clinical stage and lower OS rates in
ovarian carcinomas. Moreover, multivariate analysis indicated that NQO1 was a significant independent prognostic
factor, in addition to clinical stage, in patients with ovarian carcinoma.
Conclusions: NQO1 is frequently upregulated in ovarian carcinoma. High expressin of NQO1 protein may be an effective
biomarker for poor prognostic evaluation of patients with serous ovarian carcinomas.
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Ovarian carcinoma is one of the most lethal gynecological
carcinomas, and the second leading cause of carcinoma-
related deaths among women [1]. The majority of ovarian
carcinoma cases are of epithelial origin (> 90%), and of
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unless otherwise stated.subtype [2]. As ovarian carcinoma is often asymptom-
atic in the early stages, or presents with vague symp-
toms mimicking extra-ovarian disease, the majority of
patients (70–75%) present with widespread disease at
diagnosis, and as such the mortality rate is high [3].
Therefore, understanding the molecular pathogenesis
and mechanisms underlying ovarian cancer initiation
and progression is critical for the prevention and treat-
ment of this disease.
The NAD(P)H:quinone oxidoreductase 1 (NQO1) is a
predominantly cytosolic enzyme, which uses NADH or
NADPH as substrates to directly reduce quinones tos is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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quinones to hydroquinone by NQO1 is historically con-
sidered a detoxification mechanism, since this reaction
bypasses the formation of the highly reactive semiquin-
one [5]. NQO1 provides cells with multiple layers of
protection against oxidative stress, including the direct
detoxification of highly reactive quinones, the mainten-
ance of lipid-soluble antioxidants in reduced forms, and
stabilization of the tumor suppressor p53 [6]. Chronic
inflammation suppresses NQO1 expression and may in-
crease susceptibility to cell injury. Paradoxically, increas-
ing evidence suggests that high expression of NQO1 at
the early stages of carcinogenesis may provide cancer cells
with a growth advantage [7-9]. Moreover, certain qui-
nones, such as mitomycin C, streptonigrin, E09 and RH1,
are bioactivated by NQO1 [10-14]. The bioactivation
property of NQO1 renders it an ideal target for developing
anti-tumor drugs, since NQO1 activities are elevated in
various human tumors [15]. NQO1 was shown to be
expressed at high levels in many solid tumors, including
uterine cervix [16], lung [17] and pancreas [18], and was
also detected following the induction of cell cycle progres-
sion and proliferation of melanoma cells [19]. However, to
date, the role of NQO1 in ovarian carcinoma progression
remains unclear.
In the present study, we investigated the correlation be-
tween high expression of NQO1 and clinicopathological
features of serous ovarian carcinomas. We also assessed
the prognostic value of high NQO1 expression in patients
with serous ovarian carcinoma.Methods
Ethics statement
This study complied with the Helsinki Declaration and
was approved by the Human Ethics and Research Ethics
committees of Yanbian University Medical College of
China. Through the surgery consent form, patients were
informed that the resected specimens were stored by
our hospital and potentially used for scientific research,
and that their privacy would be maintained. Follow-up
survival data were collected retrospectively through
medical-record analyses.Patients and tissue specimens
A total of 275 human ovarian tumor specimens, including
160 serous carcinomas, 62 borderline serous tumors, 53
benign serous tumors were used for this study. These tu-
mors were selected randomly from patients undergoing
surgery between 2005 and 2010 and stored in the Tumor
Tissue Bank of Yanbian University Medical College. Patho-
logical parameters, including age, menopausal status, grade
and survival data, were carefully reviewed in all 160 serous
ovarian carcinomas.In 160 cases, patients’ ages ≥ 48 years to <48 years was
97:63. The hematoxylin and eosin-stained slides of the
different biopsies were reviewed by two experienced pa-
thologists and one appropriate paraffin block was se-
lected for this study. Histopathological grades were
made using the World Health Organization (Pathology
& Genetics Tumors of gynecological system) criteria. All
of the ovarian carcinoma patients were clinically staged
according to the FIGO staging system [with 92 early- stage
tumors (FIGO stages I and II) and 68 late-stage tumors
(FIGO stages III and IV)]. None of the ovarian carcinoma
patients received preoperative radiation or chemotherapy
before surgery. All ovarian carcinoma patients had follow-
up records for more than 5 years. By February 2014, 111
patients had died while 49 patients remained alive. The
median survival time was 44.5 months.Immunohistochemical (IHC) analysis
IHC analysis was performed using the DAKO LSAB kit
(DAKO A/S, Glostrup, Denmark). Briefly, to eliminate
endogenous peroxidase activity, 4 μm thick tissue sec-
tions were deparaffinized, rehydrated and incubated with
3% H2O2 in methanol for 15 min at room temperature
(RT). The antigen was retrieved at 95°C for 20 min by pla-
cing the slides in 0.01 M sodium citrate buffer (pH 6.0).
The slides were then incubated with the NQO1 antibody
(1:200, Santa Cruz Biotechnology, Dallas, TX, USA) at 4°C
overnight. After incubation with the biotinylated secondary
antibody at RT for 30 min, the slides were incubated with
streptavidin-peroxidase complex at RT for 30 min. Immu-
nostaining was developed by using 3,3′-diaminobenzidine
and Mayer’s hematoxylin was used for counterstaining [16].
Mouse IgG was used as an isotype control. In addition,
positive tissue sections were processed while omitting the
primary antibody (mouse anti-NQO1) as negative controls.Evaluation of the IHC staining
As described previously [20], the expressions were
scored by two pathologists (Lin Z & Liu S) who did
not possess knowledge of the clinical data. In case of
discrepancies, a final score was established by reassess-
ment on a double-headed microscope. Briefly, the immu-
nostaining for NQO1 was semi-quantitatively scored as ‘-’
(negative, no or less than 5% positive cells), ‘+’ (5–25%
positive cells), ‘++’ (26–50% positive cells) and ‘+++’ (more
than 50% positive cells). Only the cytoplasmic expression
pattern was considered as positive staining. Tissue sec-
tions scored as ‘++’ and ‘+++’ were considered as strong
positives (high expression) of NQO1. For survival data
analysis, ‘++’ or ‘+++’ scored samples were considered as
high NQO1 expression and ‘-’or ‘+’ scored samples were
considered as low NQO1 expression.
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Total RNA was extracted using TRIzol Reagent (Invitro-
gen, Carlsbad, CA, USA) from fresh tissue samples of 19
serous ovarian carcinomas and 15 benign serous ovarian
tumors. First-strand cDNA was synthesized by Prime-
Script reverse transcriptase (TaKaRa Biotechnology, Da-
lian, China) and oligo (dT) following the manufacturer’s
instructions. Real-time PCR was performed using double-
stranded DNA-specific SYBR Premix Ex Taq™ II Kit
(TaKaRa Biotechnology) on a Bio-Rad sequence detection
system according to the manufacturer’s instructions.
Double-stranded DNA specific expression was tested
by the comparative Ct method using 2-ΔΔCt. NQO1
primers were as follows: 5′-GGCAGAAGAGCACT-
GATCGTA-3′, and 5′-TGATGGGATTGAAGTTCATG
GC-3′. Primers for GAPDH, which was used as an in-
ternal control, were: 5′-GGTCTCCTCTGACTTCAACA-
3′ and 5′-ATACCAGGAAATGAGCTTGA-3′. All assays
were performed at least three times.
Statistical analysis
Statistical analyses included descriptive statistics with
determination of minimal and maximal values, means
and medians, with 95% confidence interval (CI) for par-
ticular variables. Chi-square test and Fisher’s exact test
were used to assess correlation between clinicopatholog-
ical characteristics and the expression of studied protein.Figure 1 IHC staining of NQO1 protein in ovarian tumor samples. (A)
(B–C) Weak positive expression of NQO1 protein (B) and positive expre
positive expression of NQO1 protein in serous carcinoma cells, in a pati
serous carcinoma patient without metastasis. Scattered, strongly positiv
of NQO1 protein in a serous carcinoma patient without metastasis. OrigKaplan-Meier method was used to calculate the survival
rates after tumor removal and Log-rank was used to
analyze the differences in survival curves. Multivariate
survival analysis was performed on all the significant
characteristics measured by univariate survival analysis
(age, menopausal status, histological grade, FIGO stage
and NQO1 expression) through the Cox proportional
hazard regression model. Statistical calculation was per-
formed using the SPSS 17.0. P < 0.05 was considered sta-
tistically significant.
Results
High expression of NQO1 protein in serous ovarian
carcinoma
IHC analysis of NQO1 in ovarian carcinoma cells from
160 patients revealed predominantly cytoplasmic expres-
sion (Figure 1). The rate of positive NQO1 protein ex-
pression was significantly higher in serous carcinomas
(85.6%, 137/160) than in borderline serous tumors
(56.5%, 35/62) or benign serous tumors (34.0%, 18/53)
(P < 0.01, respectively). Similarly, the rate of strong, posi-
tive NQO1 protein expression was significantly higher in
serous carcinomas (63.8%, 102/160) than in either bor-
derline serous tumors (32.3%, 20/62) or benign serous
tumors (11.3%, 6/53) (P < 0.01, respectively). More im-
portantly, the rates of positive and strongly positive
NQO1 protein expression in borderline serous tumorsNegative expression of NQO1 protein in a benign serous tumor.
ssion (C) in atypical cells of borderline serous tumors. (D) Strong
ent with metastasis. (E) Positive expression of NQO1 protein in a
e-staining cancer cells are seen (arrows). (F) Negative expression
inal magnification, A–F: ×200.
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(P < 0.05) (Table 1).
In keeping with these results, analysis of NQO1
mRNA levels by qRT-PCR confirmed elevated levels of
NQO1 transcript in serous ovarian carcinoma samples
compared with benign ovarian tumors in fresh tissues
(Figure 2).Figure 2 qRT-PCR analysis of NQO1 mRNA. Serous carcinoma
specimens (n = 19) and benign serous tumors (n = 15) were
collected, and NQO1 mRNA levels were assessed by qRT-PCR. Error
bars represent the standard deviation of the mean (SD) calculated
from three parallel experiments. **P < 0.01.Correlation between NQO1 expression status and
clinicopathological features of serous ovarian carcinoma
To evaluate the relationship between NQO1 protein and
ovarian carcinoma progression, we analyzed the correl-
ation between high NQO1 expression and clinicopatho-
logical features of ovarian carcinomas. The strongly
positive rates of NQO1 protein were significantly higher
in Grade 2 (G2) (61.7%, 29/47) and Grade 3 (G3) (69.7%,
53/76) ovarian carcinomas than those in Grade 1 (G1)
(27.0%, 10/37) cases (P = 0.000). For the FIGO clinical
stages, the strongly positive rate of NQO1 protein was
80.9% (55/68) in the late-stage (IIB–IIIC) ovarian carcin-
omas, but only 40.2% (37/92) in early-stage (I–IIA) cases
(P = 0.000). However, high expression of NQO1 protein
was not related with age, menopausal status of patients
with ovarian carcinoma (Table 2).High NQO1 expression is an independent biomarker of
poor prognosis in patients with serous ovarian carcinoma
To further substantiate the importance of high NQO1
expression in ovarian carcinoma progression, we ana-
lyzed the OS of 160 ovarian carcinoma patients using
the Kaplan–Meier method. Patients with high NQO1 ex-
pression exhibited a lower rate of OS than those with
low NQO1 expression (Log-rank = 21.699, P = 0.000)
(Figure 3A). Similarly, ovarian carcinoma patients with
high NQO1 expression had decreased OS compared
with those with low NQO1 expression in either early-
stage cases (Log-rank = 6.527, P = 0.011) or late-stage
cases (Log-rank = 4.806, P = 0.028) (Figure 3B–C). More-
over, survival of patients with G1 (Log-rank = 4.359, P =
0.037), G2 (Log-rank = 7.020, P = 0.008) and G3 (Log-
rank = 5.978, P = 0.015) ovarian carcinoma was signifi-
cantly lower in patients with tumors exhibiting high ver-
sus low NQO1 expression (Figure 3D–F).Table 1 NQO1 expression in ovarian carcinomas
Diagnosis No. of cases Positive cases
- +
Serous carcinoma 160 23 35
Borderline serous tumor 62 27 15
Benign serous tumor 53 35 12
*P < 0.05, **P < 0.01, compared with benign serous tumor.
#P < 0.01, compared with borderline serous tumor.Univariate analysis demonstrated that histological grade
(P = 0.020), FIGO stage (P = 0.000) and NQO1 expression
status (P = 0.000) were all significantly associated with OS
in patients with ovarian carcinoma. These data suggest
that NQO1 may be a valuable prognostic factor in ovarian
carcinoma. Multivariate analysis was subsequently per-
formed using the Cox proportional hazards model for all
significant variables examined in the univariate analysis.
We found that high expression of NQO1 (HR: 1.796, 95%
CI: 1.250–2.580, P = 0.002) and FIGO stage (HR: 1.736,
95% CI: 1.228–2.453, P = 0.002) were significant independ-
ent prognostic factors for survival in ovarian carcinoma
(Table 3).
Discussion
The catalytic properties of NQO1 were first reported by
Ernster and Navazio in 1958 [21]. NQO1 is predomin-
antly located in the cytoplasm, but low levels of NQO1
have also been identified in the nucleus under normal
conditions [22]. Several studies have indicated that the
phase II enzyme, NQO1, catalyzes the metabolic detoxi-
fication of quinones and protects cells against chemical-
induced oxidative stress and cancer [23,24]. The import-




67 35 85.6%**# 63.8%**#
12 8 56.5%* 32.3%*
4 2 34.0% 11.3%
Table 2 Correlation between NQO1 protein expression and the clinicopathological parameters of ovarian carcinoma
Variables No. of cases NQO1 strongly positive cases (%) χ2 P value
Age 0.161 0.689
≥48 97 57 (58.8%)
<48 63 35 (55.6%)
Menopausal status 0.050 0.823
Premenopausal 76 43 (56.6%)
Postmenopausal 84 49 (58.3%)
Histological grade 19.056 0.000**
Grade-1 37 10 (27.0%)
Grade-2 47 29 (61.7%)
Grade-3 76 53 (69.7%)
FIGO stage 26.458 0.000**
I-II 92 37 (40.2%)
III-IV 68 55 (80.9%)
**P < 0.01.
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7,12-dimethylbenz(a)anthracene- and benzo(a)pyrene-in-
duced skin cancer [25,26]. In contrast, Choi et al. demon-
strated that inhibition of NQO1 activity decreases
melanogenesis, whereas overexpression of NQO1 enhancesFigure 3 Kaplan-Meier survival curves illustrating the significance of N
with high (solid, n = 92) and low (dashed, n = 68) NQO1 expression. A: Log-rank
with poor OS in early-stage (solid, n = 37) and late-stage (solid, n = 55). B:
NQO1 expression was strongly associated with poor OS in G1 (solid, n = 10), G
E: Log-rank = 7.020, P = 0.008; F: Log-rank = 5.978, P = 0.015).pigmentation [27]. Studies using an NQO1 inhibitor sug-
gest that this oxidoreductase plays a role in inducing the
growth of pancreatic cells [28]. Beyond these reports, how-
ever, the function of NQO1 in tumor progression remains
controversial.QO1 expression in ovarian carcinomas. (A) OS rates of patients
= 21.699, P= 0.000. (B-C) High NQO1 expression was strongly associated
Log-rank = 6.527, P = 0.011; C: Log-rank = 4.806, P = 0.028. (D-F) High
2 (solid, n = 29) and G3 (solid, n = 53). D: Log-rank = 4.359, P = 0.037;
Table 3 Univariate and multivariate analysis of clinicopathological factors for the overall survival rate of 160 patients
with ovarian carcinoma
Characteristics Univariate analysis HR (95%CI) P value Multivariate analysis HR (95%CI) P value
Age 1.339(0.964-1.860) 0.082 1.391(0.992-1.951) 0.056
Menopausal status 1.115(0.815-1.525) 0.496 1.177(0.842-1.646) 0.340
Histological grade 1.268(1.038-1.548) 0.020* 1.099(0.881-1.371) 0.404
FIGO stage 1.944(1.414-2.672) 0.000** 1.736(1.228-2.453) 0.002**
NQO1 2.167(1.555-3.021) 0.000** 1.796(1.250-2.580) 0.002**
HR: hazard ratio; CI: confidence interval.
*P < 0.05, **P < 0.01.
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in the NQO1 gene affect the translation of the NQO1
protein. The NQO1 C609T polymorphism has been as-
sociated with an increased risk of various malignancies,
including lung [29], esophageal [30], gastric [31] and
uterine cervix [16] cancers. Goode et al. reported that
an NQO1 single-nucleotide polymorphism (SNP) is as-
sociated with an increased risk of ovarian cancer [32].
Moreover, high NQO1 expression has been observed in
many cancers of the liver, thyroid, breast, colon and
pancreas. Siegel et al. also found that NQO1 was over-
expressed in ovarian carcinoma compared with normal
tissue [33]. However, to date, the role of NQO1 as a
biomarker in ovarian carcinoma progression has not
been elucidated.
Here, we performed IHC staining of NQO1 protein
using 160 serous ovarian carcinomas, 62 borderline ser-
ous tumors and 53 benign serous tumors. We observed
that expression of NQO1 protein (positive and strongly
positive) was significantly higher in serous carcinomas
compared with either borderline or benign serous tu-
mors (P < 0.01). More importantly, we observed a signi-
ficant difference in the rates of positive and strongly
positive NQO1 expression between borderline serous
tumors and benign serous tumors (P < 0.05), indicating
that NQO1 may play an important role in the progression
of ovarian carcinoma. Compatible with these findings, we
also observed that the rate of strongly positive NQO1 pro-
tein expression was significantly higher in patients with
late-stage serous ovarian carcinoma, compared with early-
stage cases. Similarly, the rate of strongly positive NQO1
protein expression was higher in patients with G2 or G3,
compared with G1 ovarian carcinomas. High-grade serous
ovarian carcinoma is the most lethal form of gynecological
malignant carcinoma, and the majority of patients present
with late clinical stages (FIGO stages III and IV) of disease
at the time of diagnosis. Our data also demonstrate that
positive NQO1 expression is significantly correlated with
high-grade and late-stage ovarian carcinoma. qRT-PCR
analysis also confirmed increased levels of NQO1 mRNA
in serous ovarian carcinoma samples compared withbenign ovarian tumors in fresh tissues. These results indi-
cate that NQO1 may be a useful biomarker for poor prog-
nosis in patients with ovarian carcinoma.
Previously, we have shown that high expression of NQO1
protein was strongly associated with advanced stage, lymph
node metastasis, Her2 overexpression and shortened
survival of patients with breast cancer [34]. Moreover,
we demonstrated that high expression of NQO1 in cervical
squamous cell carcinoma patients was associated with
lower disease-free survival (DFS) and 5-year OS rates com-
pared with patients with low-level NQO1 expression [16].
Buranrat et al. also reported a significant association be-
tween high NQO1 expression and short overall survival in
cholangiocarcinoma patients, raising the exciting possibility
of using NQO1 as a tumor marker [35]. With respect to
survival, we found that ovarian carcinoma patients exhibit-
ing high NQO1 expression had lower OS rates compared
with patients with low NQO1 expression (P < 0.01).
Univariate survival analysis revealed that tumor histo-
logical grade, FIGO stage and NQO1 expression status
were all significantly related to OS of patients with ser-
ous ovarian carcinoma (P < 0.05). Further multivariate
survival analysis revealed that NQO1 expression was an
independent prognostic factor, as was FIGO stage. Our
clinical and experimental data indicate that NQO1 is a
prognostic factor and a potential therapeutic target in
patients with serous ovarian carcinoma.
Recently, NQO1 has been targeted in tumor cells,
exemplifying an ‘enzyme directed’ approach to antican-
cer drug development [36]. Kung et al. demonstrated
that β-Lapachone-induced cytotoxicity of three different
lung cancer cell lines was positively correlated with NQO1
expression and enzyme activity [37]. Hadley et al. sug-
gested that stratification of patients on the basis of NQO1
protein levels could identify a subset of esophageal squa-
mous cell carcinomas patients that may potentially benefit
from administration of low doses of 17-AAG, possibly in
combination with other chemotherapeutics [38]. Huang
et al. reported that the potency and NQO1-dependent
therapeutic window of deoxynyboquinone and its apparent
reduced metabolism by one-electron oxidoreductases
Cui et al. BMC Cancer  (2015) 15:244 Page 7 of 8make this drug (or derivatives) very promising [39]. Further
studies are therefore necessary to verify whether NQO1 in-
hibitors may be of clinical benefit to patients with ovarian
carcinoma.
Conclusions
NQO1 is frequently upregulated in ovarian carcinoma,
and its high expression predicts poor prognosis of patients
with ovarian carcinoma. NQO1 may serve as a new prog-
nostic factor and potential therapeutic target for patients
with serous ovarian carcinoma.
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